SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                  FORM 10-QSB/A

[x]  QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the quarterly period ended                       March 31, 1998
                              -------------------------------------------

                                       or

[ ]  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from _____________________ to _______________________


Commission File Number                       1-11109
                      ---------------------------------------------------

                           Lukens Medical Corporation
--------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter.)


           Delaware                                             22-2429965
-------------------------------                              ----------------
(State or other jurisdiction of                              (I.R.S. Employer
 incorporation or organization)                             Identification No.)

3820 Academy Parkway North NE, Albuquerque, NM                    87109
----------------------------------------------                  ----------
(Address of principal executive offices)                        (Zip Code)


Issuer's telephone number, including area code              (505) 342-9638
                                              ----------------------------------

Indicate by check mark whether the registrant has (1) filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.

                           Yes  X             No
                               ---              ---

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date.

         Class                                    Outstanding at March 31, 1998
----------------------------                      -----------------------------
Common Stock, $.01 Par Value                              3,093,359 Shares



<PAGE>



                   LUKENS MEDICAL CORPORATION AND SUBSIDIARIES

                                TABLE OF CONTENTS

                                                                            Page

PART I   FINANCIAL INFORMATION

         Item 1.   Financial Statements

                   Consolidated Balance Sheets                                 3

                   Consolidated Statements of Operations                       4

                   Consolidated Statements of Cash Flows                       5

                   Notes to Consolidated Financial Statements                6-8

         Item 2.   Management's Discussion and Analysis of
                   Financial Condition and Results of Operations            9-10

SIGNATURES                                                                    11



                                       2

<PAGE>



                           LUKENS MEDICAL CORPORATION

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                                (UNAUDITED)          AUDITED
                                                                                 MARCH 31,         DECEMBER 31,
                                    ASSETS                                         1998                1997
                                    ------                                    ----------------   -----------------
<S>                                                                               <C>                 <C>        
      CURRENT ASSETS:
           Cash and cash equivalents                                                  $53,882             $74,048
           Accounts Receivable, net of allowance for doubtful                      $2,262,518          $1,836,542
                accounts of $40,000 as of December 31,1997 and
                $40,000 as of March 31,1998
           Inventory                                                               $5,333,559          $5,105,900
           Prepaid Expenses                                                          $138,846            $127,080
                                                                              ----------------   -----------------
              TOTAL CURRENT ASSETS                                                 $7,788,805          $7,143,570

           Land, building and equipment, net of accumulated                        $3,537,047          $3,599,150
                Depreciation  of $1,963,377as of December 31,1997
                and $2,069,927 as of March 31,1998
           Intangible assets,                                                      $2,153,505          $2,215,420
                net of amortization  of $1,222,264 as of December 31,1997
                and $1,284,159 as of March 31,1998
           Other assets                                                               $85,754             $85,754
                                                                              ----------------   -----------------
              TOTAL ASSETS                                                        $13,565,111         $13,043,894
                                                                              ================   =================

                     LIABILITIES AND STOCKHOLDERS' EQUITY

      CURRENT LIABILITIES:
        Accounts payable                                                           $1,953,128          $1,864,832
        Accrued liabilities                                                          $134,783            $138,016
        Current maturities of long term debt                                       $6,148,257          $5,146,950
        Current maturities of obligations under capital leases                       $146,893            $146,893
                                                                              ----------------   -----------------
              TOTAL CURRENT LIABILITIES                                            $8,383,061          $7,296,691

        Long-term debt, excluding current maturities                                  $58,483             $73,483
        Stockholder Payable                                                        $1,233,075          $2,290,991
        Obligations under cap leases, excl current maturities                        $223,027            $266,256
                                                                              ----------------   -----------------
              TOTAL LIABILITIES                                                    $9,897,646          $9,927,421

        Minority interest                                                             $74,955             $74,955

      STOCKHOLDERS' EQUITY:
        Common stock, $.01 par value, authorized                                      $30,934             $30,434
             20,000,000 shares: issued and outstanding
             3,093,359  shares as of December  31,1997and  3,300,130 as of March
             31,1998.
        Additional paid-in capital                                                $18,725,535         $18,526,035
        Accumulated Deficit                                                     ($15,105,358)       ($15,461,903)
        Foreign Currency Adjustment                                                 ($58,601)           ($53,048)
                                                                              ----------------   -----------------
              TOTAL STOCKHOLDERS' EQUITY                                           $3,592,510          $3,041,518
                                                                              ----------------   -----------------
               TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                         $13,565,111         $13,043,894
                                                                              ================   =================
</TABLE>


                                        3

<PAGE>



LUKENS MEDICAL CORPORATION
CONSOLIDATED STATEMENT OF OPERATIONS
UNAUDITED

<TABLE>
<CAPTION>
                                                      THREE MONTHS
                                                          ENDED
                                                        MARCH 31,
                                                          1998                1997
                                                      --------------     ---------------
<S>                                                     <C>                 <C>      
SALES                                                    $2,658,933          $2,403,939
Cost of sales                                            $1,624,062          $1,638,284
                                                      --------------     ---------------
     GROSS PROFIT                                        $1,034,871            $765,655
                                                      --------------     ---------------

Selling expenses                                           $227,004            $228,374
General and administrative expenses                        $311,808            $218,758
Research and development expenses                           $17,098             $12,020
                                                      --------------     ---------------
          TOTAL OPERATING EXPENSES                         $555,910            $459,152
                                                      --------------     ---------------
     EARNINGS FROM OPERATIONS                              $478,961            $306,503
                                                      --------------     ---------------

OTHER EXPENSE INCOME:

     Interest income                                          ($50)            ($1,860)
     Interest expense                                      $122,466             $53,466
     Other, net                                                  $0              $1,500
                                                      --------------     ---------------
          TOTAL OTHER EXPENSE INCOME                       $122,416             $53,106
                                                      --------------     ---------------
          EARNINGS (LOSS) BEFORE INCOME TAXES              $356,545            $253,397

Income tax expense                                               $0                  $0
                                                      --------------     ---------------
          NET EARNINGS (LOSS)                              $355,545            $253,397
                                                      ==============     ===============


Basic net earnings (loss) per share                           $0.12               $0.09

Dilutive net earnings (loss) per share                        $0.11               $0.08

Weighted average number of common
    Shares outstanding - basic                            3,093,359           2,843,659

Weighted average number of common
    and common equivalent shares
    Outstanding - dilutive                                3,300,130           3,315,737
                                                      ==============     ===============
</TABLE>


                                       4

<PAGE>




LUKENS MEDICAL CORPORATION

CONSOLIDATED STATEMENT OF CASH FLOWS
UNAUDITED

<TABLE>
<CAPTION>
                                                                    THREE MONTHS
                                                                       ENDED
                                                                     MARCH 31,
                                                                        1998                1997
                                                                  -----------------     -------------
<S>                                                                     <C>                <C>      
CASH FLOWS FROM OPERATIONS:
   NET EARNINGS (LOSS)                                                    $356,545          $253,397
   ADJUSTMENTS TO  RECONCILE  NET  EARNINGS  (LOSS) TO CASH
       PROVIDED  (USED) BY  OPERATING ACTIVITIES:
        Depreciation                                                      $106,550           $82,309
        Amortization of intangible assets                                  $61,915           $37,049

   CHANGES IN CURRENT ASSETS AND LIABILITIES:
        Accounts receivable                                             ($425,976)        ($218,117)
        Inventory                                                       ($227,659)           $38,337
        Prepaids                                                         ($11,766)         ($74,849)
        Accounts payable                                                  $113,296         ($13,786)
        Accrued liabilities                                               ($3,233)          $165,534
   Change in other assets                                                       $0         ($83,606)
                                                                  -----------------     -------------
          NET CASH PROVIDED (USED) BY OPERATING ACTIVITIES               ($30,328)          $186,268
                                                                  -----------------     -------------

CASH FLOWS FROM INVESTING ACTIVITIES:
   Purchase of plant and equipment                                       ($50,000)         ($31,547)
   Investment in Joint ventures                                                 $0         ($22,913)
   Purchase of intangible assets                                                $0        ($583,689)
                                                                  -----------------     -------------
          NET CASH USED IN INVESTING ACTIVITIES                          ($50,000)        ($638,149)
                                                                  -----------------     -------------

CASH FLOWS FROM FINANCING ACTIVITIES:

   Borrowings on long term debt & obligations under capital                     $0        ($239,470)
leases
   Principal payments on long term debt & obligations under             ($139,838)         ($25,783)
capital leases
   Proceeds from the issuance of common stock and equivalents             $200,000           $13,154
                                                                  -----------------     -------------
          NET CASH PROVIDED BY FINANCING ACTIVITIES                        $60,162        ($252,099)
                                                                  -----------------     -------------
          NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS           ($20,166)        ($703,980)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD                           $74,048          $878,090
                                                                  =================     =============
CASH AND CASH EQUIVALENTS AT END OF PERIOD                                 $53,882          $174,110
                                                                  =================     =============
</TABLE>


                                       5

<PAGE>



                           LUKENS MEDICAL CORPORATION

                   Notes to Consolidated Financial Statements
                                 March 31, 1998
                                   (unaudited)

(1)  Summary of Significant Accounting Policies

     The Company's  principal  business  activity is the manufacture and sale of
     disposable surgical products. The Company's main product lines are surgical
     sutures,   lancets,   sharps  containers,   and  diagnostic  products.  The
     accompanying   unaudited   financial   statements  have  been  prepared  in
     accordance  with the  instructions  to Form  10-QSB  and  therefore  do not
     include  all  information  and  footnote  disclosure  necessary  for a full
     presentation of financial position,  results of operations, and cash flows.
     The  information  furnished,  in the opinion of  management,  reflects  all
     adjustments  necessary to present  fairly the results of  operations of the
     Company for the  three-month  period  ended  March 31,  1998 and 1997.  The
     accounting  policies  followed  by the Company are set forth in note (1) of
     Notes to the Company's  Consolidated  Financial Statements in the Company's
     Annual  Report on Form  10-KSB for the year ended  December  31,  1997,  as
     amended  (the "1997 Form  10-K")  filed with the  Securities  and  Exchange
     Commission.   The  results  of  operations  of  interim   periods  are  not
     necessarily  indicative  of  results  which may be  expected  for any other
     interim period or for the year as a whole.

(2)  Inventory

     Inventory consists of the following components at:

                                      March 31      December 31
                                        1998           1997
                                    -----------    -----------
                Raw Materials       $ 2,127,718    $ 1,938,343
                Work-in-Process       1,950,637      1,972,124
                Finished Goods        1,321,374      1,261,603
                Inventory Reserve       (66,170)       (66,170)
                                    -----------    -----------
                                    $ 5,333,559    $ 5,105,900
                                    ===========    ===========




                                        6


<PAGE>



(3)  Income Taxes

The  net  operating   loss  and  credit  for  increasing   research   activities
carryforwards as of December 31, 1997, expire as follows:

<TABLE>
<CAPTION>
                      Approximate                                      Increasing Research
                     Net Operating                                     Activities Book/Tax
                  Loss Carryforward                                           Credits
                  -----------------                                           -------

                    State Loss                Federal Loss
                      Amount                     Amount                  Tax Effect                Tax Effect
                      ------                     ------                  ----------                ----------
<S>                    <C>                      <C>                        <C>                       <C>   
   1999              $ 2,537,000               $       --              $   122,000              $     3,800
   2000                       --                1,930,000                  656,000                   37,200
   2001                3,000,000                1,835,000                  789,000                   37,500
   2002                       --                1,132,000                  385,000                    1,400
   2003                1,480,000                2,086,000                  780,000                   25,100
   2004                  315,000                  390,000                  148,000                       --
   2005                  161,000                  278,000                  102,000                       --
   2006                       --                   50,000                   17,000                       --
   2007                       --                   26,000                    9,000                       --
   2008                       --                   88,000                   30,000                       --
   2009                       --                2,760,000                  938,000
   2012                       --                3,000,000                1,020,000                       --
                     -------------------------------------------------------------
                     $ 7,493,000              $13,575,000              $ 4,996,000              $   105,000
                     ===========              ===========              ===========              ===========
</TABLE>

The  capital  loss  carryforwards  of  approximately  $271,000,  tax  effect  of
$105,000, expire in 1998.

The  deduction  of  federal  net  operating  loss  carryforwards  is  limited to
approximately $3,962,000 as of December 31, 1997. This limitation is based on an
annual  limitation of $460,000 plus  available  carryover of $654,000 and losses
incurred subsequent to 1992 of $5,248,000.  In addition,  should the sale of the
Company occur (See "Liquidity and Capital  Resources"),  there may be additional
limitations.

(4)  Pending Litigation

     Owen Mumford Ltd. ("Owen Mumford"), one of the Company's competitors, filed
     a complaint in the United States District Court for the Eastern District of
     Virginia,  Richmond  Division  on April 29,  1998 and served a summons  and
     complaint  on the  Company  on June 1, 1998,  alleging  that the one of the
     Company's products,  the "Gentle-Let 1" infringes on a patent owned by Owen
     Mumford.  The complaint seeks  unspecified  damages  adequate to compensate
     Owen  Mumford for the  alleged  patent  infringement,  as well as costs and
     expenses.   The  Company  intends  to  vigorously  defend  itself  in  this
     proceeding. The matter is currently in the discovery phase.

(5)  Status of Default Under Credit Facility

     During the quarter  ended  March 31,  1998,  the  Company was in  technical
     default of certain financial covenants and in payment default under certain
     of its term loans with its lending bank.  In April 1998,  the Company cured
     its  payment  default  under the term loans and its  lending  bank  amended
     certain  of the  financial  covenants  so that the  Company is no longer in
     default under any of its lines of credit.


                                        7

<PAGE>




(6)  Other Comprehensive Income

     The components of other comprehensive income are presented below:

   
<TABLE>
<CAPTION>
                                                                       Three months ending
                                                                            March 31, 1998
                                                                       -------------------
<S>                                                                           <C>     
         Net earnings:                                                         356,545
         Foreign currency translation adjustments                               (5,553)
                  Total comprehensive income                                  $350,992
                                                                              ========
</TABLE>
    








                                       8

<PAGE>


Item 2.              Management's Discussion and Analysis of
                  Financial Condition and Results of Operations

                              Results of Operations

Three Months Ended March 31, 1998

Sales  increased  approximately  $255,000 or 11% for the quarter ended March 31,
1998,  compared  to the  quarter  ended  March 31,  1997 due  mainly to  revenue
generated from the product lines acquired with Pro-Tec  Containers,  Inc. in May
1997 (the "Acquisition"), and due to increases in lancet sales.

The gross margin percentage  increased due to cost reductions resulting from the
manufacture of certain raw materials in India,  and the generally higher margins
in the Pro-Tec  line.  The first quarter  generated 39% margins  compared to 32%
last year.

General and  Administrative  expenses increased $94,000 to $312,000 for the 1998
quarter, versus $228,000 for the 1997 quarter. The majority of this increase was
a result of increased expenses relating to the various acquisitions in 1997, and
the addition of staff in Brazil. Sales and Marketing expenses were approximately
the same for the 1998 and 1997 quarters, and R&D increased $5,000 to $17,000 for
the 1998  quarter,  versus  $12,000 for the 1997  quarter.  The  increase in R&D
expenses reflects the cost of the Company's focus on obtaining ISO Certification
in 1998.

As a result of the foregoing, Income from Operations increased 57%, or $174,000,
to $479,000 for the 1998 quarter  versus Income from  Operations of $307,000 for
the same quarter in 1997.

Interest expense  increased $69,000 from $53,500 in 1997 to $122,000 in 1998 due
to an increase in net borrowings to finance the Acquisition in May 1997, and the
investment in the Brazil joint venture in September 1997.

As a result of the foregoing,  the Company achieved a net profit for the quarter
of $356,000,  or $.11 per share, for 1998, compared to a net profit of $253,000,
or $.08 per share, in 1997.

                         Liquidity and Capital Resources

At March 31,  1998,  the  Company had cash and cash  equivalents  of $53,882 and
working capital of $488,660.

In August 1997,  the Company's  lines of credit were renewed  through August 31,
1998. As part of this renewal, the balance on the working capital line of credit
was increased from $1,000,000 to $1,750,000,  and the letter-of-credit  line was
decreased from  $1,500,000 to $1,250,000.  As of March 31, 1998, the Company had
fully drawn the working capital line, and there were  approximately  $360,000 in
letters-of-credit  outstanding  relating to raw  material  purchases,  and other
general purposes, under the letter of credit line.


                                       9

<PAGE>



During the quarter ended March 31, 1998, the Company was in technical default of
certain  financial  covenants  and in payment  default under certain of its term
loans with its lending  bank as more fully  described  in the  Company's  Annual
Report on Form 10-KSB for the year ended  December 31, 1997. In April 1998,  the
Company  cured its payment  default  under the term loans and its  lending  bank
amended  certain of the financial  covenants so that the Company is no longer in
default under any of its lines of credit.

On April 29, 1998, the Company announced that on April 28, 1998, it entered into
an  Agreement  and Plan of Merger with  London-based  Medisys  PLC  ("Medisys"),
pursuant to which Medisys would acquire the Company, and the stockholders of the
Company  would  receive  $4.00,  in cash,  for each share of Common Stock of the
Company.  The  consummation  of the merger is subject to a number of conditions,
including  without  limitation,  approval by the  stockholders  of the  Company,
satisfactory  completion  of due  diligence and securing of financing by Medisys
sufficient to consummate the merger and the transactions  contemplated  thereby.
The merger is expected to close this summer.



                                       10

<PAGE>



                                   SIGNATURES

In accordance with the requirements of the Securities  Exchange Act of 1934, the
registrant  caused  this  report to be signed on its behalf by the  undersigned,
thereunto duly authorized.

                                           LUKENS MEDICAL CORPORATION

Date:  August 28, 1998                     By:      /s/ Robert S. Huffstodt
                                           -------------------------------------
                                           Robert S. Huffstodt
                                           President and Chief Executive Officer

Date:  August 28, 1998                     By:      /s/ Michael E. Sobieski
                                              ----------------------------------
                                           Michael E. Sobieski
                                           Chief Financial Officer


                                       11